文献速递造血干细胞移植与细胞治疗

移植物冷冻保存对异基因干细胞移植的临床影响:意大利移植注册研究(代表意大利骨髓移植组)

Clinical Impact of Graft Cryopreservation on Allogeneic Stem Cell Transplantation: An Italian, Registry-Based Study on Behalf of the "Gruppo Italiano Per Il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare" (GITMO).
PubMed 文献 · Am J Hematol · 2025-06-02

意大利骨髓移植组(GITMO)开展注册研究,纳入2018年3月至2021年9月间3492例异基因造血干细胞移植患者,比较疫情期间冷冻保存移植物队列(n=976)与历史队列(n=2516)。冷冻保存与第30天中性粒细胞和血小板植入发生率降低及造血恢复延迟相关,但原发植入失败率、II-IV级急性GVHD、复发、无复发生存无显著差异,总生存较短(校正HR=1.2,p=0.038)。

要点

  • 冷冻保存组第30天中性粒细胞和血小板植入发生率较低(校正sHR=0.8和0.7)。
  • 第30天原发植入失败率两组相似(4% vs 5%,p=0.337)。
  • 冷冻保存组总生存较短(校正HR=1.2,p=0.038)。

核心结论

  • 移植物冷冻保存与植入发生率降低和造血恢复延迟相关,且总生存较短,移植中心应仔细权衡冷冻保存的利弊。

研究设计与样本

  • 意大利骨髓移植组(GITMO)开展的基于注册的研究,纳入3492例2018年3月至2021年9月期间接受异基因造血干细胞移植的患者。
  • 冷冻保存队列(n=976)为疫情期间接受冷冻保存移植物的患者,与历史队列(n=2516)进行比较。

主要发现

  • 冷冻保存组第30天中性粒细胞和血小板植入发生率较低(校正sHR=0.8,p=0.031;校正sHR=0.7,p<0.001),造血恢复延迟。
  • 第30天原发植入失败率冷冻保存组与历史队列分别为4%和5%(p=0.337),校正后RR=1.19(p=0.518)。
  • 第100天II-IV级急性GVHD累积发生率两组相当(校正sHR=1.2,p=0.194)。
  • 慢性GVHD发生率在冷冻保存组<18岁患者中较高(校正sHR=3.9,p=0.002),在18-55岁患者中较低(校正sHR=0.7,p=0.008)。
  • 复发累积发生率(校正sHR=1.0,p=0.943)、非复发死亡(校正sHR=1.1,p=0.196)和无复发生存(校正sHR=1.1,p=0.197)两组无差异,但冷冻保存组总生存较短(校正HR=1.2,p=0.038)。

临床怎么用

  • 移植中心应仔细权衡异基因造血干细胞移植中冷冻保存的获益与弊端(作者结论)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The coronavirus disease 2019 (COVID-19) pandemic created major challenges for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Scientific societies and authorities recommended cryopreserving grafts before starting conditioning regimens, despite limited data on the clinical impact. The Italian Group for Bone Marrow Transplantation (GITMO) conducted a registry-based study involving 3492 patients who underwent allo-HSCT between March 2018 and September 2021. The cryopreserved cohort (n = 976) included patients who received cryopreserved grafts during the pandemic and was compared to the historical cohort (n = 2516). Graft cryopreservation was associated with a lower day 30 incidence of neutrophil and platelet engraftment (adjusted sHR = 0.8 and 0.7, p = 0.031 and p < 0.001, respectively) and delayed hematopoietic recovery. However, primary graft failure rates at day +30 were similar in the cryo and historical cohort (4% vs. 5%, respectively; p = 0.337), also after adjustment (RR = 1.19, p = 0.518). Day 100 incidence of grade II-IV acute GVHD was comparable between the two groups (adjusted sHR = 1.2, p = 0.194). Regarding chronic GVHD incidence, we found that it was higher in patients aged < 18 years in the cryo group (adjusted sHR = 3.9, p = 0.002), but lower in those aged 18-55 years (adjusted sHR = 0.7, p = 0.008). Cumulative incidence of relapse did not differ between historical and cryo cohort (adjusted sHR 1.0. p = 0.943), as well as non-relapse mortality (adjusted sHR 1.1, p = 0.196) and relapse-free survival (adjusted sHR = 1.1, p = 0.197). However, a shorter overall survival was observed in the cryopreserved group (adjusted HR = 1.2, p = 0.038). Transplant centers should carefully balance the benefits and drawbacks of cryopreservation in allo-HSCT.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Defrancesco I, Ferretti VV, Chiusolo P, et al. Clinical Impact of Graft Cryopreservation on Allogeneic Stem Cell Transplantation: An Italian, Registry-Based Study on Behalf of the "Gruppo Italiano Per Il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare" (GITMO). Am J Hematol. 2025. PMID: 40456127. doi:10.1002/ajh.27731

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。